Using irinotecan liposomes with chemotherapy for advanced colorectal cancer

Phase II Study of Irinotecan Liposomes Combined With 5-FU/LV+ Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer

This study is testing if a new way of giving irinotecan with chemotherapy can help people with advanced colorectal cancer live longer and feel better.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 86 (estimated)
• Ages: 18 Years to 85 Years
• Sex: All
• Sponsor: West China Hospital (Academic / other)
• Drugs / interventions: bevacizumab
• Locations: 1 site (Sichuan, Sichuan, Chengdu)
• Trial ID: NCT06341296 on ClinicalTrials.gov

What this trial studies

This Phase II clinical study aims to evaluate the efficacy and safety of irinotecan liposome injections combined with a chemotherapy regimen of 5-FU, LV, and bevacizumab in patients with inoperable metastatic colorectal cancer. A total of 86 eligible patients will receive the treatment, which includes specific dosages of the drugs administered on designated days. The study will assess various outcomes, including response rates, progression-free survival, overall survival, and safety profiles of the treatment regimen.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 85 with histopathologically confirmed inoperable metastatic colorectal adenocarcinoma and specific genetic mutations.

Not a fit: Patients who have previously received systemic antitumor therapy for their metastatic disease or those with certain health conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve survival rates and quality of life for patients with advanced metastatic colorectal cancer.

How similar studies have performed: Other studies have shown promising results with similar treatment approaches, indicating potential for success in this trial.

Eligibility criteria

Inclusion Criteria:

* 18\~85 years old.
* Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma.
* RAS/BRAF v600e mutant or right half colon cancer is known.
* pMMR/MSS is known.
* The unresectable stage of metastatic disease has not received any systemic antitumor therapy.
* For subjects previously receiving neoadjuvant or adjuvant therapy, the date of first discovery of disease progression must be at least 6 months removed from the date of last administration of neoadjuvant or adjuvant therapy.
* ECOG 0\~1, patients ≥75 years old need an ECOG score of 0
* The presence of at least 1 measurable lesion that can be evaluated according to the RECIST v1.1 criteria.
* Normal bone marrow and organ function: ① Neutrophils (ANC) ≥1.5×10\^9/L, platelets (PLT) ≥100×10\^9/L, hemoglobin (Hb) ≥80g/L, albumin (ALB) ≥30 g/L, white blood cells (WBC) ≥3.0×10\^9/L, and no bleeding tendency; ② AST, ALT and alkaline phosphatase (ALP) were all ≤2.5× upper limit of normal range (ULN), and ≤5×ULN when liver metastases occurred; The total bilirubin level doesn't exceed the upper limit of the agency's normal range; Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥40 ml/min (calculated according to Cockroft-Gault)
* Understand the situation of this study, patients and/or legal representatives voluntarily agree to participate in this study and sign informed consent form.

Exclusion Criteria:

* Known or suspected central nervous system metastasis.
* Received irinotecan/irinotecan liposomes/bevacizumab before enrollment.
* Had undergone surgery and other oncologic treatments within the first 4 weeks of enrollment.
* Previous treatment-related toxicity didn't return to NCI-CTCAE v5.0 I or below(except hair loss and peripheral neuropathy).
* The use of CYP3A, CYP2C8, and UGT1A1 inhibitors or inducers couldn't be discontinued or were not discontinued within 2 weeks prior to enrollment.
* Severe gastrointestinal dysfunction, gastrointestinal perforation, intraperitoneal abscess, and fistula.
* Intestinal obstruction, signs and symptoms of intestinal obstruction, or the stent has been previously implanted and the stent has not been removed before the screening period.
* Interstitial lung disease.
* Tendency of arterial embolism and massive bleeding within 6 months before enrollment (except surgical bleeding).
* Patients with fluid accumulation that couldn't reach a stable state but small amount of ascites on imaging without clinical symptoms could be enrolled.
* Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, heart disease, active bleeding, active viral infection, etc.
* Have had other malignancies within the past 5 years or currently, except cured cervical carcinoma in situ, uterine carcinoma in situ, and non-melanoma skin cancer.
* Patients of childbearing age who refuse to take contraceptives, women who are pregnant or breastfeeding.
* The researchers didn't consider it appropriate to participate in this study.

Where this trial is running

Sichuan, Sichuan, Chengdu

• West China Hospital，Sichuan University — Sichuan, Sichuan, Chengdu, China (Recruiting)

Study contacts

• Study coordinator: Meng Qiu, MD

Conditions Metastatic Colorectal Cancer